{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:04:37Z","timestamp":1789477477575,"version":"build-2803163510"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment-resistant depression (TRD) is a major clinical challenge, with many patients failing to respond to conventional antidepressants. Psychedelic compounds such as psilocybin and ayahuasca have recently gained attention as potential rapid-acting therapies. Beyond their neurobiological effects, methodological, ethical, and real-world applicability concerns are critical for understanding their clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review of literature on psilocybin and ayahuasca in adult patients with TRD, focusing on safety, efficacy, and study design characteristics. PubMed and PsycINFO databases were searched from inception to August 2025. Studies were assessed for clinical outcomes, side effect profiles, and methodological and ethical limitations, including participant selection, blinding, and informed consent procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both psilocybin and ayahuasca demonstrate rapid reductions in depressive symptoms, with psilocybin showing more robust evidence for sustained effects. However, clinical trials are predominantly conducted in highly controlled environments with stringent inclusion and exclusion criteria, systematically excluding patients with comorbidities, high suicide risk, or polypharmacy. Challenges in maintaining blinding, high participant expectations, small sample sizes, and reliance on adjunct psychotherapy further limit the interpretation and generalizability of findings. Ethical considerations, including informed consent for intense psychedelic experiences and the potential for enduring personality or cognitive changes, remain under-addressed. Consequently, current evidence primarily reflects outcomes in clinically stable and selected subpopulations, rather than real-world TRD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Psychedelic-assisted therapies hold significant potential for TRD, but their current evidence base is constrained by methodological and ethical limitations. Future research should prioritize large, representative trials, standardized protocols, and robust safeguards to ensure both scientific validity and patient safety. Unlike previous reviews that primarily synthesized efficacy outcomes across different psychedelic compounds, the present narrative review specifically compares psilocybin and ayahuasca within the framework of treatment-resistant depression while integrating methodological, ethical and real-world implementation issues. This perspective aims at complementing the existing evidence by highlighting factors that may influence future clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1858319","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:02:31Z","timestamp":1789473751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review"],"prefix":"10.3389","volume":"17","author":[{"given":"Serena Chiara","family":"Civardi","sequence":"first","affiliation":[{"name":"Department of Mental Health and Addiction, Azienda Socio Sanitaria Territoriale (ASST) Melegnano e della Martesana","place":["Vizzolo Predabissi, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Besana","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Addiction, Azienda Socio Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Durbano","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Addiction, Azienda Socio Sanitaria Territoriale (ASST) Melegnano e della Martesana","place":["Vizzolo Predabissi, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Otto Maria","family":"Toscano","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Addiction, Azienda Socio Sanitaria Territoriale (ASST) Rhodense","place":["Garbagnate Milanese, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Raffone","sequence":"additional","affiliation":[{"name":"Dipartimento di Salute Mentale e Fisica e Medicina Preventiva, Universit\u00e0 degli Studi della Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]},{"name":"Department of Mental Health, Azienda Sanitaria Locale (ASL) Napoli 1 Centro","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Maria","family":"Dell\u2019Osso","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Addiction, Azienda Socio Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco","place":["Milan, Italy"]},{"name":"Department of Biomedical and Clinical Sciences \u201cLuigi Sacco,\u201d University of Milan","place":["Milan, Italy"]},{"name":"Department of Psychiatry and Behavioral Sciences, Bipolar Disorders Clinic, Stanford University","place":["Stanford, CA, United States"]},{"name":"\u201dAldo Ravelli\u201d Center for Neurotechnology and Brain Therapeutic, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Olivola","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Addiction, Azienda Socio Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62381-9","article-title":"Temporal and spatial trend analysis of all-cause depression burden based on Global Burden of Disease (GBD) 2019 study","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1155\/da\/5553491","article-title":"Trends in prevalent cases and disability-adjusted life-years of depressive disorders worldwide: Findings from the Global Burden of Disease Study from 1990 to 2021","volume":"2025","author":"Chen","year":"2025","journal-title":"Depress Anxiety"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.2688","article-title":"Association of mental disorders with subsequent chronic physical conditions: World Mental Health Surveys from 17 countries","volume":"73","author":"Scott","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3109\/01612840.2013.831260","article-title":"World Health Assembly adopts comprehensive Mental Health Action Plan for 2013-2020","volume":"34","author":"Thomas","year":"2013","journal-title":"Issues Ment Health Nurs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00390-6","article-title":"Addressing the burden of mental, neurological, and substance use disorders: Key messages from Disease Control Priorities, 3rd edition","volume":"387","author":"Patel","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-007-0064-0","article-title":"Rapid onset of true antidepressant action","volume":"9","author":"Taylor","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.07.005","article-title":"Onset, time course and trajectories of improvement with antidepressants","volume":"22","author":"Lam","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716659417","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can J Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Control Clin Trials"},{"key":"B10","article-title":"Treatment resistant depression","volume-title":"Psychopharmacology: The Fourth Generation of Progress","author":"Thase","year":"1995"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(02)01670-0","article-title":"Is treatment-resistant depression a unique subtype of depression","volume":"53","author":"Fagiolini","year":"2003","journal-title":"Biol Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J Affect Disord"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2009.04.027","article-title":"Antidepressant electroconvulsive therapy: Mechanism of action, recent advances and limitations","volume":"219","author":"Merkl","year":"2009","journal-title":"Exp Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14090949","article-title":"Repetitive transcranial magnetic stimulation for the treatment of depression in a real-world setting: Findings from a cohort study","volume":"14","author":"Prodi","year":"2024","journal-title":"Brain Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J Affect Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2023.06.016","article-title":"Investigating the effectiveness and tolerability of intranasal esketamine among older adults with treatment-resistant depression (TRD): A post-hoc analysis from the REAL-ESK Study Group","volume":"31","author":"d'Andrea","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0200","article-title":"Esketamine combined with SSRI or SNRI for treatment-resistant depression","volume":"82","author":"Del Casale","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"B23","volume-title":"The Doors of Perception. On the Author's Sensations Under the Influence of the Drug Mescalin","author":"Huxley","year":"1954"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: Past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211003495","article-title":"Psychedelics: Old drugs, new trips","volume":"35","author":"Rucker","year":"2021","journal-title":"J Psychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat Neurosci"},{"key":"B28","article-title":"Seeking the magic mushroom","volume":"42","author":"Wasson","year":"1957","journal-title":"Life"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.2164-0947.1959.tb00681.x","article-title":"Division of mycology: The hallucinogenic mushrooms of Mexico: An adventure in ethnomycological exploration","volume":"21","author":"Wasson","year":"1959","journal-title":"Trans N Y Acad Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/BF02159243","article-title":"Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim","volume":"14","author":"Hofmann","year":"1958","journal-title":"Experientia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852922000888","article-title":"Psilocybin in neuropsychiatry: A review of its pharmacology, safety, and efficacy","volume":"28","author":"Dodd","year":"2023","journal-title":"CNS Spectr"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacol (Berl)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.Bpsc.2024.04.001","article-title":"Dynamic functional hyperconnectivity after psilocybin intake is primarily associated with oceanic boundlessness","volume":"9","author":"Mortaheb","year":"2024","journal-title":"Biol Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5960","article-title":"Acute adverse effects of therapeutic doses of psilocybin: A systematic review and meta-analysis","volume":"7","author":"Yerubandi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2024.104060","article-title":"Safety pharmacology of acute psilocybin administration in healthy participants","volume":"3","author":"Straumann","year":"2024","journal-title":"Neurosci Appl"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1134454","article-title":"Therapeutic effect of psilocybin in addiction: A systematic review","volume":"14","author":"van der Meer","year":"2023","journal-title":"Front Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.9758\/cpn.23.1120","article-title":"Psilocybin, an effective treatment for major depressive disorder in adults - A systematic review","volume":"22","author":"Watford","year":"2024","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102799","article-title":"Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: Observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial","volume":"76","author":"Erritzoe","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/00005053-199602000-00004","article-title":"Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil","volume":"184","author":"Grob","year":"1996","journal-title":"J Nervous Ment Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s0378-8741(98)00168-8","article-title":"Pharmacokinetics of Hoasca alkaloids in healthy humans","volume":"65","author":"Callaway","year":"1999","journal-title":"J Ethnopharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/2050312113508389","article-title":"Ayahuasca and cancer treatment","volume":"1","author":"Schenberg","year":"2013","journal-title":"SAGE Open Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X16666180125095902","article-title":"Ayahuasca: Psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness","volume":"17","author":"Hamill","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00330","article-title":"Hypothesis: The psychedelic ayahuasca heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process","volume":"9","author":"Inserra","year":"2018","journal-title":"Front Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1080\/14740338.2022.2054988","article-title":"Ayahuasca, a potentially rapid acting antidepressant: Focus on safety and tolerability","volume":"21","author":"Rossi","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2026.1726909","article-title":"The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: Modulation of the depressive burden in a longitudinal study","volume":"17","author":"Camargos","year":"2026","journal-title":"Front Psychiatry"},{"key":"B53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/JCP.0000000000002122","article-title":"The therapeutic potential of psychedelics for treatment-resistant depression: Reality or hallucination? A systematic review","volume":"46","author":"Horato","year":"2026","journal-title":"J Clin Psychopharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(02)01866-8","article-title":"The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacol (Berl)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.09.133","article-title":"Single-dose psilocybin for U.S. military veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study","volume":"369","author":"Ellis","year":"2025","journal-title":"J Affect Disord"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20231063","article-title":"Single-dose psilocybin for depression with severe treatment resistance: An open-label trial","volume":"182","author":"Aaronson","year":"2025","journal-title":"Am J Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.12.061","article-title":"The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression","volume":"372","author":"Goodwin","year":"2025","journal-title":"J Affect Disord"},{"key":"B67","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol Psychiatry"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2013.15.2\/lripoll","article-title":"Psychopharmacologic treatment of borderline personality disorder","volume":"15","author":"Ripoll","year":"2013","journal-title":"Dialogues Clin Neurosci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00185","article-title":"Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls","volume":"9","author":"Galv\u00e3o","year":"2018","journal-title":"Front Psychiatry"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00733","article-title":"Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development","volume":"9","author":"Schenberg","year":"2018","journal-title":"Front Pharmacol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100727","article-title":"Psychedelic-assisted psychotherapy: Hope and dilemma","volume":"32","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.887255","article-title":"Psychedelic-assisted psychotherapy-a systematic review of associated psychological interventions","volume":"13","author":"Cavarra","year":"2022","journal-title":"Front Psychol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2021.100240","article-title":"Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies","volume":"6","author":"Gard","year":"2021","journal-title":"J Affect Disord Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1221131","article-title":"Manic episode following psilocybin use in a man with bipolar II disorder: A case report","volume":"14","author":"Halim","year":"2023","journal-title":"Front Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.psycr.2024.100243","article-title":"The many faces of psilocybin-related psychosis: A case series","volume":"4","author":"Kim","year":"2025","journal-title":"Psychiatry Res Case Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.24.1180","article-title":"A case report of psilocybin-induced psychosis in a predisposed patient","volume":"22","author":"Morris","year":"2024","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","article-title":"Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies","volume":"76","author":"Perez","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-014-0020-y","article-title":"Switch to mania after ayahuasca consumption in a man with bipolar disorder: A case report","volume":"3","author":"Szmulewicz","year":"2015","journal-title":"Int J Bipolar Disord"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2019.09.621","article-title":"P.644 ayahuasca-induced mania as first presentation of bipolar disorder: A clinical case and literature review","volume":"29","author":"Fernandes","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcp.2019.10.005","article-title":"Psychosis induced by abuse of ayahuasca: A case report","volume":"50","author":"Palma-\u00c1lvarez","year":"2021","journal-title":"Rev Colomb Psiquiatr (Engl Ed)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcpeng.2022.08.008","article-title":"Ayahuasca-induced psychosis: A case report","volume":"51","author":"Cer\u00f3n Tapia","year":"2022","journal-title":"Rev Colomb Psiquiatr (Engl Ed)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2024-260648","article-title":"Drug-induced psychosis following use of ayahuasca: A presentation to forensic psychiatric services","volume":"17","author":"Baker","year":"2024","journal-title":"BMJ Case Rep"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01325","article-title":"The impact of ayahuasca on suicidality: Results from a randomized controlled trial","volume":"10","author":"Zeifman","year":"2019","journal-title":"Front Pharmacol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2018.04.016","article-title":"Treatment-resistant depression and suicidality","volume":"235","author":"Bergfeld","year":"2018","journal-title":"J Affect Disord"},{"key":"B93","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jpsychires.2021.01.014","article-title":"Treatment-resistant depression and risk of all-cause mortality and suicidality in Danish patients with major depression","volume":"135","author":"Gronemann","year":"2021","journal-title":"J Psychiatr Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2113692","article-title":"Observational study to characterize treatment-resistant depression in Germany, France and the United Kingdom: Analysis of real-world data collected through a survey of healthcare professionals","volume":"38","author":"Orsini","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"B95","article-title":"Acute suicidal behavior following ayahuasca ingestion in a clinical trial setting: A case report","volume-title":"Braz J Psychiatry","author":"Reis","year":"2025"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: Guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front Pharmacol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119655","article-title":"Long-term outcomes of single-dose psilocybin for U.S. military veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study","volume":"389","author":"Ellis","year":"2025","journal-title":"J Affect Disord"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911450","article-title":"Esketamine and psilocybin-the comparison of two mind-altering agents in depression treatment: Systematic review","volume":"23","author":"Psiuk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B100","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41398-025-03654-3","article-title":"Psychedelics and ketamine\/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes","volume":"15","author":"d'Andrea","year":"2025","journal-title":"Transl Psychiatry"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.14650","article-title":"Developing an ethics and policy framework for psychedelic clinical care: a consensus statement","volume":"7","author":"McGuire","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2024.104092","article-title":"An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers","volume":"4","author":"Godfrey","year":"2024","journal-title":"Neurosci Appl"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2025.105519","article-title":"Is there room for ethics of authenticity in psilocybin research","volume":"4","author":"Jerotic","year":"2025","journal-title":"Neurosci Appl"},{"key":"B104","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12152-024-09550-9","article-title":"Psychedelic therapy as form of life","volume":"17","author":"Langlitz","year":"2024","journal-title":"Neuroethics"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis","volume":"8","author":"Hieronymus","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.12900","article-title":"Psychedelic therapy-a new paradigm of care for mental health","volume":"330","author":"Yehuda","year":"2023","journal-title":"JAMA"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2024.2410853","article-title":"Psychedelic therapy - refining the claim of a paradigm shift","volume":"36","author":"Aicher","year":"2024","journal-title":"Int Rev Psychiatry"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02478-9","article-title":"Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension","volume":"29","author":"Smith-Apeldoorn","year":"2024","journal-title":"Mol Psychiatry"},{"key":"B109","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4088\/JCP.14077su1c.01","article-title":"Assessing the risk factors for difficult-to-treat depression and treatment-resistant depression","volume":"77","author":"Gaynes","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2026.121257","article-title":"Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: evidence from real-world studies","volume":"401","author":"de Oliveira Lapa","year":"2026","journal-title":"J Affect Disord"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.737738","article-title":"Translating psychedelic therapies from clinical trials to community clinics: building bridges and addressing potential challenges ahead","volume":"12","author":"Williams","year":"2021","journal-title":"Front Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1858319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:02:34Z","timestamp":1789473754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1858319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":111,"alternative-id":["10.3389\/fpsyt.2026.1858319"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1858319","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1858319"}}